Insider Selling: Definium Therapeutics (NASDAQ:DFTX) Insider Sells $513,845.07 in Stock

by · The Markets Daily

Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report) insider Mark Sullivan sold 14,051 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $513,845.07. Following the transaction, the insider owned 494,228 shares in the company, valued at approximately $18,073,917.96. This trade represents a 2.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Definium Therapeutics Price Performance

DFTX stock traded down $0.20 during trading hours on Tuesday, hitting $38.21. 1,967,182 shares of the stock traded hands, compared to its average volume of 2,245,960. The stock has a 50-day simple moving average of $41.37 and a 200 day simple moving average of $32.06. Definium Therapeutics, Inc. has a one year low of $10.46 and a one year high of $49.70. The company has a market cap of $5.13 billion, a P/E ratio of -11.14 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities analysts forecast that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

DFTX has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Definium Therapeutics in a report on Monday, September 14th. Bank of America started coverage on Definium Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $75.00 price target on the stock. Stifel Nicolaus upped their price objective on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Needham & Company LLC reissued a “buy” rating and issued a $66.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. Finally, Oppenheimer restated an “outperform” rating and set a $75.00 price target on shares of Definium Therapeutics in a report on Monday, September 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $64.88.

Get Our Latest Research Report on Definium Therapeutics

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors have recently made changes to their positions in the business. Sequoia Financial Advisors LLC acquired a new position in shares of Definium Therapeutics during the second quarter valued at about $812,000. WINTON GROUP Ltd acquired a new position in Definium Therapeutics in the 2nd quarter valued at approximately $240,000. Engineers Gate Manager LP bought a new stake in shares of Definium Therapeutics in the 2nd quarter worth approximately $481,000. Integrated Wealth Concepts LLC bought a new stake in shares of Definium Therapeutics in the 2nd quarter worth approximately $159,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Definium Therapeutics during the 2nd quarter worth approximately $222,000. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Company Profile

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

Further Reading